Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1 antibody:

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.10.16
Views: 2764

Dr Omid Hamid - The Angeles Clinic, California, USA

Dr Hamid speaks with ecancertv at ESMO 2016 about the outcomes of a phase I study into the responses to combined PD-1 and PD-L1 inhibition in multiple tumour sites.

PD-1 and PD-L1 have been targets of immune checkpoint inhibitor therapy independently across multiple cancer types and sites, and Dr Hamid describes the initial results of co-targeting both at once.

He introduces upcoming phase II trials in bladder cancer, and considers how to improve patient responses for those expressing either high or low levels of the biomarkers.

ecancer's filming at ESMO 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation